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Despite the evidences showing the relevance of regulator y immune -mediated mech anisms to guarantee 
the stable graft function in renal transplanted patients, studies focusing on the immune response 
observ ed over a long-term period after renal transplantation are still limited. Several efforts have been 
done to establish novel biomarkers with relevant predictive values that could be used as prognostic lab- 
oratorial tools to monitor the complex netwo rk triggered through time after kidney transplantation. In
this study, we have evaluated the pro-inﬂammatory and regulatory patterns of plasma cytokine s in a
group of 120 renal transplanted patients with stable graft function ranging from 1 to 160 months. Our 
data demonstrated an overall predominance of regulatory cytokines short-term after renal transplanta- 
tion (1–24 months) with peaks of IL-4, IL-5 and IL-10. Moreover, a slight peak of TNF- a was observed 25–
60 months after renal transplantation. Following a gap of stable cytokine proﬁle (61–120 months), peaks 
of pro-inﬂammatory cytokines IL-8, IL-6, IL1 b, TNF- a and IL-12 were observ ed later on (>120 months)
after renal transplantation. Additionally, the categorical analysis of ‘‘low’’ or ‘‘high’’ cytokine producers 
re-enforc e the occurrence of an overall regulatory status early-after stable renal graft function with a pre- 
dominant pro-inﬂammatory pattern later on long-term renal transplantation. Taken together, our data 
suggest that IL-5 is a good biomarker associated with short-term stable renal function, whereas IL-12 
seems to be a relevant pro-inﬂammatory element in long-term renal transplanted patien ts.
 2013 Elsevier Ltd.   Open access under the Elsevier OA license.1. Introduction 
Renal transplanta tion is the better choice for treatment of end 
stage renal disease. Nevertheless, after renal transplanta tion pa- 
tients need permanent immunosupp ressive treatment to prevent 
graft rejection and loss. Despite great improvements in renal allo- 
graft survival over the last three decades, long-term graft loss, par- 
ticularly through antibody-med iated rejection, remains the great 
challenge of renal transplanta tion [1–3].
Recent studies have suggested that cytokine s plasma assess 
after renal transplanta tion could allow a better understand ing of
the renal allograft rejection pathogen esis, as well as to predict fu- 
ture rejection process [2–7]. Besides, cytokines gene polymor- 
phisms have been correlated with increased production of these 
cytokines [8,9].Análises Clínicas e Toxicoló-
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sevier OA license.Cytokine s are generally responsib le for TH1 and TH2 responses 
in renal transplanta tion. TH1 lymphocytes produce IL-2, TNF- a and
IFN-c. By activation of macrophages , these lymphocytes partici- 
pate in delayed hypersensitivity and cytotoxic activity. TH2 lym- 
phocytes produce IL-4, IL-5, IL-6, IL-10, IL-13 and participate in
the production of antibodies. Deregulated production of pro- 
inﬂammatory or regulator y cytokine s plays an important role in
the disease susceptibility and progression of renal transplanta tion 
[5–7]. Therefore, induction of speciﬁc immunologic tolerance with 
suppressi on of IL-6, IL-12, TNF- a and others proinﬂammatory cyto- 
kines remains as an important goal of organ transplanta tion [10–
12].
The aim of this study was to evaluate the cytokines plasma lev- 
els in renal transplanted patients with stable graft function. It
should be highlighted that this is the ﬁrst study evaluating a wide 
cytokine proﬁle in distinct periods post-trans plant. This study can 
contribute to expanding the understa nding about the immune re- 
sponse after renal transplantation and provide novel biomarker s
with relevant predictive values that could be used as laboratorial 
tools for prognostic and monitoring purposes.
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2.1. Patients 
A total of 120 renal transplante d patients were selected at two 
Renal Transplant Units, in Belo Horizonte, Minas Gerais, Brazil from 
2010 to 2011. The study population comprises 82 males and 38 fe- 
males with age ranging from 19 to 73 years and time post-transp lan- 
tation ranging from 1 to 160 months. All patients have received 
kidney from living organ donors. Pre-transp lant panel reactive 
anti-HLA antibody was negative in 49 receptors, positive in 8 and 
not available for 63 patients. All patients were under corticostero id
therapy at their inclusion in this study. Triple immunosup pressive 
protocol with tacrolimus + mycophenolate mofetil + predniso ne
was given to 51.6% of patients and ciclosporin + mycophenol ate 
mofetil + predniso ne to 35.0% of patients. A small group of patients 
(13.4%) were treated with prednisone associated with other immu- 
nosuppressive drugs. Seven out of 120 patients presente d previous 
CMV infection short-term after renal transplant. These patients 
were included in the present investiga tion since they showed nega- 
tive CMV antigenemia at the blood collection. The inclusion criterion 
was stable graft function and the exclusion criteria were acute or
chronic allograft rejection. Rejection was deﬁned by an increase in
creatinine plasma levels by 0.3 mg/dL from baseline that was not 
attributed to other causes with subsequent return to baseline after 
treatment with pulse steroids or anti-lym phocytic antibodies [13].
The study population was categorized into four subgroups accordin g
to the time after transplanta tion and included G1: patients within 1–
24 months; G2: patients within 25–60 months; G3: patients within 
61–120 months and G4: patients 121–160 months post-transp lant.
These subgroup s typify distinct posttransplantati on phases includ- 
ing early (G1), intermediate (G2 and G3) and long-term (G4) survival 
with stable graft function. Four out of 29 patients from the G4 sub- 
group presente d previous and sporadic episodes of renal dysfunc- 
tion after renal transplanta tion, all of them were considered to
present stable graft function at the time of their inclusion in the 
present study. The major demograph ic and clinical features of these 
subgroups are presented in Table 1.
2.2. Ethics 
This study was approved by the Ethics Committee at Federal 
University of Minas Gerais and informed consent was obtained 
from all participants. The research protocol did not interfere with 
any medical recomme ndations or prescriptions.
2.3. Plasma samples 
Five mL whole blood samples were drawn in EDTA-K 3 1.8 mg/ 
mL (Vacuette) and centrifuged at 1300 g for 20 min at 4 C to ob- 
tain the plasma samples. Plasma aliquots were stored at 70 C
until use for ﬂow cytometric cytokine measureme nts.
2.4. Cytometric beads array for cytokine measuremen ts
Cytokine plasma levels were determined using commercially 
available kits, including Human Th1/Th2 Cytometric Beads Array Table 1
Demographic and clinical features of the study population a.
Groups Time post-transplant (months) N
G1 1–24 31
G2 25–60 30
G3 61–120 30
G4 121–160 29
Total 1–160 120 
a Time post-transplant are expressed as min–max, creatinine levels as mean ± SD and– CBA (BD Bioscienc es Pharmingen, USA) to quantify IFN- c, IL-4 
and IL-5 along with the Human Inﬂammation kit to quantify IL- 
1b, IL-6, IL-8, IL-10, TNF- a and IL-12.
The CBA immunoassay uses 7.5 lm polystyrene microbeads,
assembled in distinct ﬂuorescent sets, unique on their type 4 ﬂuo-
rescence intensity (FL-4). Each microbead is coupled to monoclonal 
antibody (MAb) against a given cytokine. Following incubation 
with the test sample, the bead-cap tured cytokine s were detected 
by direct immunoa ssay using a ‘‘detection cocktail’’ of distinct 
MAbs labeled with type 2 ﬂuorescence, phycoerythrin- PE (FL-2).
The method was carried out as recommended by the manufac-
turer, modiﬁed as follows: brieﬂy, 25 lL of undiluted plasma samples
or standards (previously diluted) were added to 15 lL of bead-mix
and incubated for 90 min at room temperature in the dark. The cyto-
kine standard curves were run daily for each assay. After incubation,
the samples and standards were washed with 500 lL of wash buffer
and centrifuged at 600g for 7 min at room temperature. Subse-
quently, 20 lL of detection cocktail were added to each tube and
the bead-mix re-incubated for 90 min at room temperature in the
dark. Following incubation, the samples and standards were washed
again with 500 lL of wash buffer and centrifuged at 600g for 7 min at
room temperature to remove unbound detector reagent. After wash-
ing, 250 lL of wash buffer was added to each tube. Data acquisition
and analysis was performed in dual-laser FACScalibur™ ﬂow cytom-
eter (BD Biosciences Pharmingen, San Jose, CA, USA), using the BD Bio-
science CBA software. Although the ﬂuorescently labeled particles in
the BD CBA immunoassay are designed to be excited by the 488 nm
and 532 nm lasers on other BD ﬂow cytometers, they can also be ex-
cited by the red diode laser 633 nm on dual-laser BD FACSCalibur
instruments. The detection of beads emission at FL-4 channel simpli-
ﬁes the instrument set-up procedure and reduces the need for ﬂuo-
rescence compensation. Thus, a total of 1800 beads/tube were
acquired after proper set-up of a ﬂow cytometer. Results were ex-
pressed as mean ﬂuorescence intensity (MFI) for each cytokine.2.5. Analysis of ‘‘overall cytokine patterns’’ and ‘‘cytokine signatures’’
The plasma cytokine levels were initially analyzed as the mean 
ﬂuorescent intensity provided by the CBA immunoassay s and re- 
ferred as ‘‘overall cytokine patterns’’. Each cytokine pattern was 
ﬁrst expressed as moving average of plasma cytokines according 
to the time after renal transplanta tion. Following study population 
sub grouping categorization, the median overall cytokine patterns 
were compared amongst G1, G2, G3 and G4 subgroups. Additional 
analysis referred as ‘‘cytokine signatures’’ were also performed as
previousl y proposed by Luiza-Silva et al. [14]. Brieﬂy, the global 
median value for each cytokine was calculated taking the whole 
data universe from all renal transplante d patients. The global med- 
ian cut off were used as the cut-off edge to tag each patient as they 
display ‘‘Low levels’’ ( for all cytokine s), high levels of pro- 
inﬂammatory ( for IL-8, IL-6, IL-1 b, TNF- a, IL-12, IFN- c) or high 
levels of regulatory ( for IL-4, IL5 and IL-10) cytokine s. After 
assembli ng of gray-scal e diagrams for each study subgroup, the 
frequenc y (%) of patients showing ‘‘High cytokine levels’’ was cal- 
culated. This strategy allowed for computation of the percentage Creatinine levels (mg/dL) Gender (M/F) Age (years)
1.7 ± 0.9 22/09 36 (19–63)
1.5 ± 0.6 19/11 45 (21–66)
1.5 ± 0.5 21/09 49 (33–73)
1.6 ± 0.5 20/09 47 (33–64)
1.6 ± 0.7 82/38 44 (19–73)
 age as median (min–max).
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kine signature’’ for each subgroup was then assembled as the 
ascendant frequency of high cytokine levels of G1, G2, G3 and G4.
2.6. Statistical analysis 
The cytokine patterns were ﬁrst evaluated consideri ng the mov- 
ing average of plasma cytokine levels, expressed as mean ﬂuores-
cence intensity (MFI), along to the time post-transplan tation to
identify, for each cytokine, the post-transp lant period associate d
with peaks of maximum MFI. Upon study population subgrouping 
categorization, compara tive analysis amongst subgroups were per- 
formed by Kruskal–Wallis followed by Dunn’s post-test and differ- 
ences considered signiﬁcant at P < 0.05. Prior statistical analysis,
the normality of data distribution was evaluated by the Kolmogo- 
rov–Smirnov test. All statistical comparisons were performed using 
the program GraphPad PRISM (version 5.0).
An additional strategy of data analysis were used to tag each pa- 
tient as they present ‘‘Low’’ or ‘‘High’’ cytokine levels, taking the 
global median MFI value from all data universe of a given cytokine 
as the cut-off. The frequency of patients with High cytokine levels 
were then compiled to establish the cytokine ascendant proﬁle re- 
ferred as ‘‘cytokine signatures’’. Relevant cytokine frequency was 
considered when the percentage of patients with high cytokine 
levels was above the 50th percentile. Further, comparative analysis 
of the cytokine signatures among subgroup s were performed by
overlapping the ascendant cytokine curves of each subgroup of re- 
nal transplante d patients. Relevant differences in the ascendant 
cytokine signatures among subgroup s were identiﬁed by compar- 
ative analysis, considering for each subgroup only the cytokine s
with frequency above the 50th percentile.3. Results 
3.1. Analysis of ‘‘overall cytokine patterns’’ and ‘‘cytokine signatures’’
An overall predominance of regulatory cytokines is observed 
short-term after renal transplanta tion, while increased levels of
pro-inﬂammatory cytokines are found later on long-term renal 
transplanta tion.
Aiming to characterize the overall cytokine pattern of renal 
transplante d patients, we have ﬁrst evaluated the moving average 
of plasma cytokine levels accordin g to the time after transplantation 
to identify, for each cytokine, the post-transp lant period associated 
with increased MFI (Fig. 1). Our ﬁnding demonst rated that there was 
an increase tendency of IL-4, IL-5 and IL-10 in renal transplante d pa- 
tients within 1–24 months post-trans plantation. On the other hand,
a tendency of increased levels of IL-8, IL-6, IL-1 b and TNF- a was ob- 
served in patients with more than 120 months of renal transplanta- 
tion. Similarly , a tendency of increased TNF- a was also observed in
patients within 25–60 months post-trans plantation. IFN- c levels re- 
mained steady along the time post-transp lantation (Fig. 1).
3.2. The categorical analysis of low or high cytokine producers 
highlighted the occurrence of an overall regulatory status early-after 
stable renal graft function with a predominant pro-inﬂammatory 
pattern later on long-term renal transplantation 
Aiming to further characterize the cytokine proﬁle, we have used 
a novel strategy to analyze the frequency of renal transplante d pa- 
tients with distinct levels of plasma cytokines, categorized as
‘‘low’’ or ‘‘high’’ cytokine producer, as previously proposed by Lui- 
za-Silva et al. [14]. The global median values was determined for 
each cytokine , including IL-8 = 1.8, IL-6 = 8.4, IL-1 b = 2.4, TNF- 
a = 4.5, IL-12 = 5.3, IFN- c = 4.0, IL-4 = 1.3, IL-5 = 1.4 and IL-10 = 6.0,all expresse d in mean ﬂuorescence intensity (MFI). These standards 
were further used as a cut-off to tag each patient as they present 
‘‘low’’ ( ) or ‘‘high’’ levels of pro-inﬂammatory ( ) or regulator y
( ) plasma cytokine s (Fig. 2A). Following, gray-scale diagrams 
were created to calculate for each study subgroup, the frequency 
(%) of patients displaying high cytokine levels (Fig. 2B). Our data 
highlight ed that whereas G1 (1–24 months) displayed increased 
frequenc ies (upper than 50th percentile) of patients with regulator y
status (IL-4 = 71%, IL-5 = 71% and IL-10 = 52%), the subgroup G2
(25–60 months) showed prominent frequency of patients with 
pro-inﬂammatory pattern (IL-1b = 57%, TNF- a = 60% and IFN- 
c = 64%). Although G3 (61–120 months) and G4 (121–160 months)
presente d a mixed cytokine proﬁle, the G3 showed a balanced 
proﬁle of pro-inﬂammatory and regulatory cytokine s (IL-8 = 53%
and IL-10 = 57%), whereas G4 displayed a predominant pro- 
inﬂammatory proﬁle (IL-8 = 62%, IL-6 = 62%, IL-1 b = 66%, TNF- 
a = 59%, IL-12 = 76% and IL-5 = 64%) (Fig. 2B).
3.3. Cytokine signatures pointed out IL-5 as a putative biomarker 
associate d with short-term stable renal function and IL-12 as a
relevant pro-inﬂammatory event in long-term renal transplanted 
patients
To further evaluate the cytokine mediated immune response in
renal transplanted patients, we have generated the inﬂammatory/ 
regulator y ascendant cytokine signatures for each subgroup , using 
the 50th percentile as the signiﬁcance baseline (Fig. 3A). Our data 
showed that the outstanding regulatory status of G1 (1–
24 months) was characterized by IL-5 = IL-4 > IL-10 with no signif- 
icant contributions of any other cytokine evaluated. On the other 
hand, G2 (25–60 months) displayed a pro-inﬂammatory cytokine 
proﬁle signed by IFN- c > TNF- a > IL-1 b. The G3 (61–120 months)
subgroup was characterized by a balanced cytokine signature com- 
posed by IL-10 > IL-8. Finally, predominant pro-inﬂammatory cyto- 
kine signature was observed in G4 (121–160 months) with higher 
than 50th percentile for IL-12 > IL-1 b > IL-5 > IL-8 = IL-6 > TNF- a
(Fig. 3A).
The analysis of the overlappi ng cytokine ascendant curves fur- 
ther illustrated the relevant role of IL-5 in the early phase of stable 
graft renal function after transplanta tion and the prominent 
involvem ent of IL-12 as a pro-inﬂammatory element later during 
long-term renal transplanta tion (Fig. 3B).
3.4. Semi-quanti tative analysis revealed that plasma levels of IL-5 and 
IL-12 are useful laboratorial tools for prognosti c and monitoring 
purposes in renal transplanted patients 
The comparison of the median cytokine plasma levels observed 
at distinct time ranges after renal transplanta tion is shown in
Fig. 4. Our ﬁndings demonst rated higher levels of IL-5 (P = 0.008)
in G1 (1–24 months) as compared to G2 (25–60 months). More- 
over, higher levels of IL-12 (P = 0.015) was observed in G4 (121–
160 months) as compared to G3 (61–120 months). No signiﬁcant
differenc es were observed for the median plasma levels of all other 
cytokine evaluated.4. Discussion 
Tolerance or rejection to transplanted allografts usually refers 
to the adaptation of the recipient’s immune system to recognize 
donor alloantig ens and controls alloreact ivity or the establishment 
of an intense reactivity to the transplanted graft. Both mechanisms 
are mediated by cellular immune response supported by
cytokine -mediated events [15]. The pro-inﬂammatory/regulatory 
cytokine network is known to play a crucial role controlling this 
121-160 months 121-160 months 121-160 months
121-160 months121-160 months
Fig. 1. Overall cytokine patterns in renal transplanted patients. Data are expressed as mean ﬂuorescence intensity (MFI) and presented as moving average of IL-8, IL-6, IL-1 b,
TNF- a, IL-12, IFN- c IL-4, IL-5 and IL-10 plasma levels, along to the time after renal transplantation (1–160 months). The range lines referring to 1–24, 25–60, 61–120 and 121–
160 months highlight the post-transplant periods associated with peaks of maximum MFI values for each cytokine. These peaks were used to support the subgrouping 
categorization of the study population.
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temic cytokine s proﬁle can be observed as early as 6–24 h after 
surgery and are known to drive the immune response towards 
rejection or tolerance [5,6,10,16,17]. Pro-inﬂammatory cytokines 
such as IL-2 and IL-15 mediates the rejection process, whereas 
modulatory cytokines, such as IL-10 and TGF- b participa te in the 
tolerance mechanisms. These ﬁndings are critical to the fail or suc- 
cess of renal grafting, especially in the ﬁrst year after transplanta -
tion [5,6,11].
The most of others publications were performed short-term 
after transplanta tion. It should be highlighted that a few studies 
evaluating cytokines plasma levels over a long period after renal 
transplanta tion were found on the literature. The understanding 
of the immune response associate d with short and long-term renal 
transplanta tion would provide knowledge and new insights about 
the mechanisms underlyin g the tolerance or rejection of kidney 
grafts.
The availability of plasma panels from renal transplanted pa- 
tients has enabled an unprecedented comparative analysis of plas- 
ma cytokines during early and late phases of stable renal 
transplanta tion. Aiming to identify putative immunolog ical fea- 
tures to be used as complemen tary biomarkers to monitor stable renal transplanta tion, we have performed a cross-sectional analy- 
sis of changes in pro-inﬂammatory/regu latory plasma cytokines,
accordin g to the time of renal transplanta tion.
In the present investigatio n, we have observed an overall pre- 
dominan ce of regulatory cytokines short-term after renal trans- 
plantatio n (1–24 months), with peaks of IL-4, IL-5 and IL-10 
being the major ﬁndings (Fig. 1). In fact, IL-5 has been identiﬁed
as a signiﬁcant biomarker associated with short-term stable renal 
function (Fig. 4). Involvemen t of IL-5 in immune tolerance is not 
fully understo od. It has been admitted that high levels of IL-5 in re- 
cent post-transp lant period is related to immunosuppre ssive ther- 
apy for immunologica l tolerance induction, which is mainly used 
in this period [16]. At this time, no evident predominance of pro- 
inﬂammatory proﬁle could be observed . Consistent with this data 
it has been shown that in the ﬁrst 2 years after transplanta tion 
only mild degree of inﬂammation is usually observed and also mild 
ﬁbrosis that do not qualify for the diagnosis of rejection [17,18].
A slight peak of TNF- a was observed 25–60 months after renal 
transplanta tion. After 2 years post-trans planted the immunosup- 
pression is usually reduced, which justify the decrease in regula- 
tors cytokines and the shift towards a more pro-inﬂammatory 
proﬁle. Assessment of TNF- a plasma levels in patients with 
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Fig. 2. Categorical analysis of low or high cytokine producers in subgroups of renal transplanted patients. The global median values was determined for each cytokine,
including IL-8, IL-6, IL-1 b, TNF- a, IL-12, IFN- c, IL-4, IL-5 and IL-10, all expressed in mean ﬂuorescence intensity (MFI). These standards were further used as a cut-off to tag 
each patient as they present ‘‘low’’ ( ) or ‘‘high’’ levels of pro-inﬂammatory ( ) or regulatory ( ) plasma cytokines (A). Gray-scale diagrams were used to compile the 
patients displaying high cytokine levels of each subgroup of renal transplanted patients, including G1 (1–24 months), G2 (25–60 months), G3 (61–120 months) and G4 (121–
160 months) (B). The sample size of each subgroup (N), the number (sum of high) and the frequency (%) of patients displaying high cytokine levels are provided in the ﬁgure.
Prominent cytokine frequencies, above the 50th percentile, are highlighted in bold underline.
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paring to control group (18). In our study, no signiﬁcant differences 
were observed in the plasma levels of TNF- a amongst the sub- 
groups evaluated (Fig. 4). It is possible that subject-speci ﬁc partic- 
ularities in the degree of post-operative healing, inﬂammation and 
interstitial ﬁbrosis in the studied subgroup could count for these 
ﬁndings, since although it is expected that 5 years after transplan- 
tation most patients will present some level of inﬂammation and 
ﬁbrosis, both glomerulopath y and inﬂammation is signiﬁcantly
variable within these groups of patients [17–19].
Following a gap of stable cytokine proﬁle (61–120 months), our 
data demonstrate that peaks of pro-inﬂammatory cytokines IL-8,
IL-6, IL1 b, TNF- a and IL-12 can be observed later on (121–
160 months) after renal transplanta tion (Fig. 1). However, only 
IL-12 was a signiﬁcant pro-inﬂammatory element in long-term re- 
nal transplante d patients (Fig. 4). Again, we believe that changes in
the immunossup ressive treatment protocol applied to late-stable 
renal transplanted patients, with lower modulato ry properties 
are the events underlyin g the up-regulation of IL-12 observed .
Immunosup pressive drugs are known to enhance the production 
of suppress the production of IL-12 [20]. One possibilit y is that 
the dosage of immunosup pression directly affects the balance ofregulator y/pro-inﬂammatory cytokine s, as previousl y reported 
for the frequency of circulating dendritic cells expression IL-10 
and IL-12 [21]. Consistent with this pro-inﬂammatory plasma cyto- 
kine pattern observed , it has been reported that plasma IL-10 is
down-re gulated late post-trans plant as compare d with early 
post-trans plant [21]. However, in the present investigation no
change in the levels of IL-10 was observed . Recent studies have 
demonst rated that down regulation of pro-inﬂammatory cyto- 
kines, especially IL-12, is associated with short-term transplant tol- 
erance. On the other hand, increase in pro-inﬂammatory cytokine s
may be associate d with the decline of renal function, especially in
the long term [15,22].
Complemen tary data analysis was applied to evaluate the plas- 
ma cytokine proﬁle amongst groups, using the general concept of
‘‘Low’’ and ‘‘High’’ cytokine producers (Fig. 2A) as proposed by Lui- 
za-Silva et al. [14]. Following data assembling on multi-cytok ine 
diagrams , the frequency of High cytokine producers was calculated 
for each group (Fig. 2B). The comparative analysis of High cytokine 
producers amongst the subgroups of renal transplanted patients 
was performed using the 50th percentile as a limit to identify rel- 
evant differences [14]. The compara tive analysis of cytokine signa- 
tures pointed out that early after renal transplanta tion there is an
(A)
(B)
G4 (121-160 months)
G4 (121-160 months)
Fig. 3. Cytokine signatures of subgroups of renal transplanted patients. The cytokine pattern was expressed as the ascendant frequency of high cytokine producers for each 
subgroup of renal transplanted patients, including G1( 1–24 months), G2( 25–60 months), G3( 61–120 months) and G4( >120 months). Column charts (A) and 
overlay curves (B) were used to identify changes in the overall cytokine signature amongst subgroups. Prominent cytokine frequencies, above the 50th percentile dotted line,
are highlighted by rectangles (B).
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IL-5, consistent with the peaks observed in the analysis of moving 
average showed in the Fig. 1. In fact, this regulatory cytokine 
microenvironm ent maybe expected at 1–24 months post-trans- 
plantation, since at the beginning of post-transp lant immunossu- 
pression the patients undergo to the ‘‘inductio n therapy’’,referred as ‘‘state of immunossup ression’’ combining classic immu- 
nossupres sive drugs (corticosteroids, CSA, TAC, AZA, MMF) with 
supportiv e therapy for CMV [23].
A balanced cytokine signature was observed in patients within 
61–120 months after transplanta tion, characterized by enhanced 
frequenc y of patients with high plasma levels of pro-inﬂammatory 
Fig. 4. Cytokines plasma levels in subgroups of renal transplanted patients. Data are expressed as mean ﬂuorescence intensity (MFI) and presented as median + inter-quartile 
range of IL-8, IL-6, IL-1 b, TNF- a, IL-12, IFN- c IL-4, IL-5 and IL-10 plasma levels observed in G1( 1–24 months), G2( 25–60 months), G3( 61–120 months) and 
G4( 121–160 months). Comparative analyses amongst subgroups were performed by Kruskal–Wallis followed by Dunn’s post-test. Signiﬁcant differences at P < 0.05 are 
highlighted by connecting lines.
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levels of the regulator y cytokine IL-10. It is possible to infer that 
these patients who survive more than 5 years post-transp lantation 
reached equilibrium between pro-inﬂammatory and regulatory 
cytokines, which will be broken with the aging of the kidney 
transplante d.
In fact, more than 50% of patients within the 121–160 months sub-
group showed increased plasma levels of most pro-inﬂammatory
cytokines evaluated (IL-8, IL-6, IL-1b, TNF-a and IL-12) (Fig. 3). This
cytokine signature analysis corroborate the analysis of moving
average (Fig. 1) that showed peaks of pro-inﬂammatory cytokines
IL-8, IL-6, IL1b, TNF-a and IL-12 as the most prominent changes in
the cytokine network elements observed late post-transplant. De
Serres et al. [7] have also demonstrated that long-term glomerulopa-
thy in renal transplanted patients (14 years after transplantation) is
associated with higher plasma levels of pro-inﬂammatory cytokines,
including IL-1b, IL-6 and TNF-a. It is noteworthy that later on after re-
nal transplantation, it is expected that patients become carelessness
with the immunosuppressive medication, since they are living for a
long time in good conditions with the transplanted kidney, favoring
the overcome of a pro-inﬂammatory response.
The major advantage of applying the cytokine signature model 
for data analysis was the opportun ity to detect, with higher sensi- 
bility, putative minor changes in the cytokine proﬁle not detect- 
able by conventional statistical approach es.Addition al longitudina l studies are still necessar y to character- 
ize the plasma cytokine proﬁle in patients showing distinct postre- 
nal grafting outcome to clarify the applicability of these 
biomarker s as a prognostic tool within complex immunologica l
alteration s after renal transplanta tion. Moreover, as only plasma 
samples were available from the donors studied here, it was not 
possible to address the cellular sources of the elevated levels of
cytokine s. However , it is important to notice that the pattern of
changes in the cytokine levels observed accordin g to the time fol- 
lowing renal grafting would be consistent with a theoretical ex- 
pected response involving distinct immunosupres sion therapy 
applied at different after transplanta tion.
It is important to mention that the cross-sectio nal design of the 
present investigation may offer restrictions to deﬁne causal rela- 
tionship between the immunolog ical and clinical ﬁndings. How- 
ever, it should be emphasized that cross-sectio nal studies are 
essential to provide insights and guide further longitudina l studies.5. Conclusion s
Taken together, our data suggest that IL-5 is a good biomarker 
associate d with short-term stable renal function, whereas IL-12 
seems to be a relevant pro-inﬂammatory element in long-term re- 
nal transplante d patients.
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